ECCO Abstract Awards

Long term maintenance treatment with vedolizumab in pediatric IBD: a three-year follow-up of the prospective multicenter VEDOKIDS study.
Dan Turner, Jerusalem, Israel

Infliximab induction fails to reach targets in Perianal Fistulizing Crohn’s Disease: first results from the ATLANTIC study.
Lieven Mulders, Amsterdam, The Netherlands

Caudovirales may trigger molecular mimicry mechanisms in Crohn’s Disease.
Carmela Errico, Milan, Italy

Mucosal deficiency of mitochondria-driven humoral immunity is linked to Crohn’s Disease.
Annika Raschdorf, Lübeck, Germany

Active disease on intestinal ultrasound in pregnancy is associated with an increased risk of adverse obstetric and neonatal outcomes: an international multi-centre prospective cohort study.
Emma Flanagan, Fitzroy, Australia

Efficacy of appendectomy in inducing remission in moderate-to-severe ulcerative colitis: preliminary one year results of a multicentre prospective cohort study (COSTA).
Eva Visser, Amsterdam, The Netherlands

TDM-Based Dose-Intensification of Infliximab is not Superior to Standard Dosing in Patients with Acute Severe Ulcerative Colitis: Results from the TITRATE Study.
Joep Van Oostrom, Amsterdam, The Netherlands

Vedolizumab counteracts Parkinson’s disease-related brain pathology driven by gut-primed IBD T cells.
Elizaveta Gerasimova, Erlangen, Germany

Translational and preclinical study validating anterior gradient 2 as a novel epithelial therapeutic target in Inflammatory Bowel Disease (IBD) involved in inflammation, fibrosis, and intestinal barrier integrity.
Xavier Tretón, Neuilly, France

Development of a core outcome set for Inflammatory Bowel Disease patients with stomas.
Lakshman Kumar, Dublin, Ireland

Emulsifier restriction is an effective therapy for active Crohn’s disease: the ADDapt trial - a multi-centre, randomised, double-blind, placebo-controlled, re-supplementation trial in 154 patients.
Aaron Bancil, London, United Kingdom

Geographic disparities in Healthcare Utilisation in people with inflammatory bowel disease, Crohn’s Colitis Cure Data Insights Program.
Jane Mary Andrews, Sydney, Australia

A necroptotic-to-apoptotic signaling axis underlies inflammatory bowel disease.
Britt Christensen, Parkville, Australia

Circulating neutrophils exhibit distinct transcriptional and maturity changes in CD and UC that relate to pathogenic Th1/17 CD4+ memory T cell responses.
M. Fernanda Pascutti, Rotterdam, The Netherlands

Patient-specific regulatory network rewiring in Inflammatory Bowel Disease: How genetic polymorphisms divert incoming signals and contribute to disease pathogenesis.
John P Thomas, London, United Kingdom